cevidoplenib

Cevidoplenib is an orally available, low-molecular-weight, synthetic small molecule that acts as a highly potent and selective inhibitor of spleen tyrosine kinase (SYK). By inhibiting SYK-mediated intracellular signaling, particularly downstream of B-cell receptors (BCR) and Fc receptors in immune cells such as B cells, macrophages, neutrophils, mast cells, and natural killer (NK) cells, cevidoplenib blocks the activation and proliferation of these inflammatory cells. This leads to anti-inflammatory and immunomodulatory effects. Cevidoplenib is being developed primarily for the treatment of autoimmune diseases—most notably immune thrombocytopenia (ITP)—and has demonstrated efficacy in increasing platelet counts in patients with persistent or chronic ITP who have failed prior therapies. The drug has completed phase 2 clinical trials for ITP and received Orphan Drug designation from the FDA for this indication[1][2][4][5][6][7].

Other names

cevidoplenib mesylate1703788-21-9UNII-3N3H8BX897UNII3N3H8BX897UNII 3N3H8BX897